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Summary
Sialuria is a rare inborn error of metabolism character-
ized by cytoplasmic accumulation and increased urinary
excretion of free N-acetylneuraminic acid (NeuAc, sialic
acid). Overproduction of NeuAc is believed to result
from loss of feedback inhibition of uridinediphosphate-
N-acetylglucosamine 2-epimerase (UDP-GlcNAc 2-epi-
merase) by cytidine monophosphate-N-acetylneura-
minic acid (CMP-Neu5Ac). We report the cloning and
characterization of human UDP-GlcNAc 2-epimerase
cDNA, with mutation analysis of three patients with
sialuria. Their heterozygote mutations, R266W, R266Q,
and R263L, indicate that the allosteric site of the epi-
merase resides in the region of codons 263–266. The
heterozygous nature of the mutant allele in all three pa-
tients reveals a dominant mechanism of inheritance for
sialuria.
Introduction
Free N-acetylneuraminic acid (NeuAc) is a negative-
ly charged carbohydrate present in most tissues and
body fluids as the terminal acidic residue of N-linked
glycoproteins (Schauer 1982). In the first committed
step of NeuAc synthesis, UDP-N-acetylglucosamine
(UDP-GlcNAc) is converted to N-acetylmannosamine
(ManNAc) and UDP by UDP-GlcNAc-2-epimerase (fig.
1). This enzyme is feedback inhibited by the activated
sialic acid donor, CMP-Neu5Ac (Kornfeld et al. 1964;
Sommar and Ellis 1972), which also provides NeuAc for
placement on glycoconjugates in the trans-Golgi (Beau-
det and Thomas 1995). The glycoconjugates are even-
tually degraded in lysosomes, and one of the first steps
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is removal of a NeuAc residue by neuraminidase (Som-
mar and Ellis 1972). The resultant free NeuAc is trans-
ported out of lysosomes by a membrane carrier (Gahl
et al. 1995; Renlund et al. 1986) that also recognizes
glucuronic acid (Blom et al. 1990). NeuAc is filtered but
not reabsorbed by the human kidney (Seppala et al.
1990).
Several human disorders of sialic acid metabolism
have been recognized (Gahl et al. 1996). Sialidosis is due
to deficiency of lysosomal neuraminidase activity (Beau-
det and Thomas 1995), and galactosialidosis results
from a defect in the protein that stabilizes galactosidase
and neuraminidase (Galjart et al. 1988). In both of these
disorders, conjugated or bound NeuAc is stored within
lysosomes. In Salla disease and infantile free sialic acid
storage disease (ISSD), unconjugated NeuAc accumu-
lates in lysosomes because of defective transport across
the lysosomal membrane (Mancini et al. 1986; Renlund
et al. 1986; Tietze et al. 1989). ISSD, observed world-
wide (Tondeur et al. 1982; Stevenson et al. 1983), ap-
pears to be a more severe form of Salla disease, which
occurs primarily among Finnish people (Aula et al. 1979;
Renlund et al. 1983). In a different NeuAc storage dis-
ease, sialuria (MIM 269921), free sialic acid accumulates
in the cell cytoplasm, and gram quantities of NeuAc are
excreted in the urine (Montreuil et al. 1968; Thomas et
al. 1985; Wilcken et al. 1987). Using fibroblasts cultured
from sialuria patients, we previously demonstrated that
the metabolic defect involves lack of feedback inhibition
of UDP-GlcNAc 2-epimerase by CMP-Neu5Ac, causing
constitutive overproduction of free NeuAc (Weiss et al.
1989; Seppala et al. 1991; Krasnewich et al. 1993). The
four reported cases of sialuria (Montreuil et al. 1968;
Wilcken et al. 1987; Seppala et al. 1991; Krasnewich et
al. 1993) are characterized by variable degrees of de-
velopmental delay, coarse facial features, and hepato-
megaly. Whether sialuria is a dominant or a recessive
disorder has not been determined.
The rat UDP-GlcNAc 2-epimerase, a bifunctional en-
zyme possessing N-acetylmannosamine (ManNAc) ki-
nase activity as well as epimerase activity (Hinderlich et
al. 1997; Stasche et al. 1997), has been sequenced, and
this provides a basis for investigating the human dis-
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Figure 1 The N-acetylneuraminic acid synthetic pathway, show-
ing feedback inhibition of UDP-GlcNAc 2-epimerase by CMP-
Neu5Ac.
order, sialuria. To elucidate the molecular mechanism
for defective allosteric regulation of UDP-GlcNAc 2-epi-
merase in this disease, we cloned and sequenced the hu-
man cDNA for the enzyme and determined the muta-
tions in the three available sialuria patients.
Subjects and Methods
Patients and Cells
Patient 1 was A.W., described byWilcken et al. (1987)
as a 2-year-old girl with moderate developmental delay,
hepatosplenomegaly, slightly coarse facial features, a
large tongue, macrocephaly, and massive urinary excre-
tion of free sialic acid. At age 7 years, she had mild
intellectual impairment, with fine-motor difficulty, but
attended regular school (Don and Wilcken 1991). Her
growth was at the 10th percentile, and the organomegaly
persisted. Patient 2 was J.C., reported by Weiss et al.
(1989). This 10-month-old boy had hepatomegaly and
a coarse voice and facial features. His growth and de-
velopment, however, remained normal at least through
5 years of age (Gahl et al. 1996). Patient 3 was T.W.,
extensively described by Krasnewich et al. (1993). This
4.5-year-old boy exhibited hepatomegaly, dysmorphic
facies, and hirsutism, but normal growth. At age 6 years,
his full-scale IQ was 68.
Fibroblasts from patient 1 were kindly provided by
Drs. Bridget Wilcken (Sydney, Australia) and John Hop-
wood (Adelaide, Australia). Cells from patient 2 were
sent by Drs. Greg Barsh and Seymour Packman (San
Francisco), and cells from patient 3 by Drs. Wilma
Krause (Atlanta) and David Wenger (Philadelphia). The
fibroblasts were propagated in Dulbecco’s modified Ea-
gle’s minimum essential medium fortified with 10% fetal
calf serum (Gibco), 2 mM glutamine, nonessential amino
acids, and antibiotics as described elsewhere (Renlund
et al. 1986; Tietze et al. 1989).
Molecular Studies
We used the sequence of the recently cloned rat UDP-
GlcNAc 2-epimerase (Hinderlich et al. 1997; Stasche et
al. 1997) to search for homologous human sequences in
the dbEST database with an NBI BLAST server. Three
human sequences matched various regions of the rat
sequence, on the basis of predicted amino acid se-
quences. Oligonucleotides designed from the human se-
quences served as primers to PCR amplify the human
cDNA from a liver cDNA library (Marathon Ready,
Clontech). We determined the 5′ flanking sequence by
PCR amplification using Marathon Ready cDNA con-
taining a universal AP adaptor. We identified the 3′ flank-
ing sequence by PCR amplification using the SuperScript
human liver cDNA library and a T7 universal primer.
Restriction enzyme digestion, ligation, and cloning
procedures were performed as described elsewhere (Sam-
brook et al. 1989). PCR amplifications were done for
35 cycles (94C for 30s, 65C for 30s, and 72C for 2
min), followed by a single incubation at 72C for 10
min. DNA sequence analysis was performed by means
of the T7 Quick Denature Plasmid sequencing kit (Amer-
sham Life Sciences).
Mutation Analysis
We prepared fibroblast RNA, using Trizol Reagent
(Life Technologies). It was converted to cDNA by the
SuperScript Pre-amplification System (Life Technologies)
and was used as a template for PCR amplification.Direct
and clonal sequencing were performed with Amersham’s
Sequenase PCR Product and the Plasmid Sequencing
Kits, respectively. Each patient’s cDNA was subjected to
analysis for sequence anomalies by using BESS-T Scan
TMMutation Detection and Localization Kit (Epicentre
Technologies) according to the manufacturer’s instruc-
tions.
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Figure 3 Northern blot of UDP-GlcNAc 2-epimerase gene ex-
pression in various human tissues.
Figure 2 Nucleotide sequence and deduced amino acid sequence
of human UDP-GlcNAc 2-epimerase/ManNAc kinase. Divergent
amino acids in the rat sequence (SwissProt accession number Y07744)
are shown above the human amino acid sequence. Divergent nucle-
otides in the rat sequence are shown below the human nucleotide
sequence. Numbering of the amino acids starts with the putative in-
itiation methionine and follows the rat sequence. The end of the coding
region is indicated by an asterisk (∗). Two clusters of amino acid
residues that comprise putative ATP-binding regions are shaded, and
the critical residues of a putative leucine zipper of the predicted kinase
domain (Stasche et al. 1997) are boxed.
Northern Blot Analysis
A multiple-tissue northern blot was obtained from
Clontech and hybridized by means of a probe containing
nucleotides 777–1452 of the human UDP-GlcNAc 2-
epimerase cDNA, as described elsewhere (Sambrook et
al. 1989).
Expression and Epimerase Assay
Using the GST Gene Fusion System (Pharmacia Bio-
tech), we accomplished expression of UDP-GlcNAc 2-
epimerase by inserting the cDNA into vector pGEX-2T
and transforming Escherichia coli BL21 with this vec-
tor. After induction with isopropyl-b-D-thiogalactoside,
the cells were harvested and extract supernatants as-
sayed for epimerase activity. The conversion of UDP-
[3H]GlcNAc to [3H]ManNAc was assayed as described
elsewhere (Seppala et al. 1991), with detection of prod-
ucts by high-pH anion-exchange chromatography on a
BioLC carbohydrate analyzer (Dionex). For thermosta-
bility studies, fibroblast extracts were incubated at 37C
for 0, 2, 10, and 30 min prior to assay of epimerase
activity. Epimerase activity was expressed as picomoles
of ManNAc produced per milligram of protein per
minute.
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Figure 4 UDP-GlcNAc 2-epimerase mutations in three patients with sialuria. Sequences encompass codons 263–266. A, Normal control.
B, Patient 1, showing missense change R266W due to a CrT transition in the third base of codon 266. C, Patient 2, showing missense change
R266Q due to a GrA transition in the second base of codon 266. D, Patient 3, showing a missense change R263L due to a GrT transversion
in the second base of codon 263.
Results
The full-length sequence of the human UDP-GlcNAc
2-epimerase, as judged by the presence of an open read-
ing frame, exhibited 98.6% identity with the rat se-
quence at the amino acid level and 88% identity at the
nucleotide level (fig. 2). Two putative ATP-binding sites
were localized to the carboxy-terminal half of the se-
quence on the basis of a comparison with known ATP-
binding domains of hexokinases (fig. 2). A separate com-
parison revealed 50% similarity of the amino terminal
part of our human sequence with the UDP-GlcNAc 2-
epimerases of Bacillus subtilis (SwissProt Protein Se-
quence Data Bank accession number P39131), E. coli
(SwissProt accession number P27828) and Salmonella
borreze (SwissProt accession number P52642), placing
the epimerase activity in the amino-terminal portion of
the protein.
Northern blot analysis using a multiple tissue filter
revealed a single band of ∼5.5 kb with a high level of
expression of the human UDP-GlcNAc 2-epimerase in
liver and placenta (fig. 3).
The cDNAs of three sialuria patients were subjected
to BESS-T Scan analysis (Epicentre Technologies), which
revealed sequence anomalies indicative of point muta-
tions in the UDP-GlcNAc 2-epimerase/ManNAc kinase
gene. Subsequent sequencing of wild-type and mutant
subclones verified the point mutations in one allele of
each patient (fig. 4). For patients 1 and 2, the anomaly
was in codon 266; for patient 3, it was in codon 263.
Consistent with pathologic mutations, each base change
led to replacement of a positively charged arginine with
an amino acid of different charge or solubility: hydro-
phobic tryptophan in patient 1, neutral glutamine in
patient 2, and hydrophobic leucine in patient 3. For each
patient, a cDNA clone that did not contain the base
alteration of the mutant clone was completely se-
quenced; no amino acid–altering base changes were
found. Northern blot analysis revealed normal size and
amount of UDP-GlcNAc 2-epimerase RNA in each pa-
tient’s fibroblasts (data not shown).
Full-length cDNA clones of a normal and mutant
UDP-GlcNAc 2-epimerase gene were expressed inE. coli
and assayed for epimerase activity. Bacteria transfected
with vector alone gave virtually no background activity;
there was no conversion of 3H-UDP-GlcNAc to
ManNAc (data not shown). Bacteria transfected with
the normal allele of patient 1 showed significant epi-
merase activity, with substantial production ofManNAc
(fig. 5). This was inhibited 85% by 100 mM CMP-
Neu5Ac, consistent with normal allosteric inhibition
(Seppala et al. 1991). The extract of E. coli transfected
with plasmid containing the mutant epimerase gene of
patient 3 showed normal ManNAc production from
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Figure 5 UDP-GlcNAc 2-epimerase enzymatic activity expressed
in E. coli. The substrate, UDP-[3H]GlcNAc (7.5 nmol in a final volume
of 112.5 ml), was incubated for 6 min at 37C in the presence of 50
ml of E. coli extract with 100 mM CMP-Neu5Ac absent (left panel)
or present (right panel). [3H]GlcNAc elutes first in fractions 30–35,
whereas the product of the epimerase, [3H]ManNAc, elutes in later
fractions. CMP-Neu5Ac inhibits the epimerase, reducing the amount
of [3H]ManNAc produced. A, Epimerase activity of E. coli expressing
the normal allele of patient 1. Epimerase activity was inhibited nor-
mally (i.e., 85%) by 100 mM CMP-Neu5Ac. B, Epimerase activity of
E. coli expressing the mutant allele of patient 3. The epimerase activity
is not decreased, but it is inhibited only 15% by 100 mM CMP-
Neu5Ac.
UDP-GlcNAc, but this epimerase activity was inhibited
only 15% by 100 mM CMP-Neu5Ac (fig. 5).
The thermostability of the normal and sialuria en-
zymes was investigated by measuring UDP-GlcNAc 2-
epimerase activity in nontransfected fibroblast extracts
that were incubated for various lengths of time at 37C.
Control fibroblasts exhibited a half-life of 12 min for
the epimerase activity, compared with 13 min for the
sialuria fibroblasts (patient 3). In duplicate experiments,
the mean baseline epimerase activity of the control fi-
broblasts was 37 pmol of ManNAc/mg protein/min,
compared with 70 pmol/mg protein/min for the sialuria
cells.
Discussion
As shown by Stasche et al. (1997), the rat UDP-
GlcNAc 2-epimerase is bifunctional, possessing both the
2-epimerase activity and ManNAc kinase activity. The
rat enzyme self-associates as a fully active hexamer and
as a dimer with only kinase activity. The human enzyme,
with nearly 99% identity to the rat enzyme at the amino
acid level, also appears bifunctional. The ATP-binding
sites and the presence of a leucine zipper motif (a pu-
tative dimerization domain) in the carboxy terminus of
the protein suggest that the kinase activity resides there
(Stasche et al. 1997). This assignment is supported by
the similarity of nucleotides 417–722 of our human se-
quence with those of the glucose kinases of Staphylo-
coccus xylosus, Streptomyces coelicolor, and B. subtilis
and with hexokinase A of Saccharomyces cerevisiae.
Similarity of the human amino terminal sequence with
other epimerases places the epimerase activity in the pro-
tein’s amino-terminal portion. The clustering of patients’
mutations in codons 263–266 strongly suggests that this
is the allosteric site for CMP-Neu5Ac binding.
Since only one allele of each sialuria patient contained
a mutation, and expression studies using a patient’s nor-
mal allele resulted in normal, inhibitable epimerase ac-
tivity (fig. 5), the disease appears dominant in inheri-
tance. That is, heterozygosity for a mutated allosteric
site of UDP-GlcNAc 2-epimerase is sufficient to cause
sialuria. In this case, the mutant epimerase activity con-
tinues to produce free sialic acid and CMP-Neu5Ac,
which inhibits the normal but not the mutant epimerase.
With no brake on the rate-limiting step in sialic acid
production, intracellular free sialic acid levels increase
indefinitely, leading to the clinical and laboratory find-
ings of sialuria. Dominant inheritance has also been re-
ported in the hyperinsulinism and hyperammonemia
syndrome, in which GTP fails to feedback-inhibit glu-
tamate dehydrogenase because of mutations affecting
the enzyme’s allosteric site (Stanley et al. 1998). In sial-
uria, the absence of any symptoms in the parents of the
affected children indicates that the base changes repre-
sent new mutations. Parental DNA was not available
for direct analysis.
The exact mechanism by which the three epimerase
mutations cause dysregulation of sialic acid synthesis
remains unknown. The standard explanation is that
CMP-Neu5Ac fails to feedback inhibit UDP-GlcNAc 2-
epimerase. However, the two-fold increase in baseline
epimerase activity of sialuria fibroblasts, reported in the
present study and elsewhere (Weiss et al. 1989), suggests
that greater stability of the enzyme may also contribute
1568 Am. J. Hum. Genet. 64:1563–1569, 1999
to increased sialic acid production. This hypothesis was
not supported by our normal in vitro thermostability
measurements. Still, there may be factors that increase
epimerase stability in vivo and were not measured in
vitro. For example, the CMP-Neu5Ac of sialuria cells
may bind to the allosteric site of the epimerase and sta-
bilize the enzyme in vivo but may be released by the in
vitro extraction, resulting in normal stability measure-
ments. Alternatively, the extracted epimerase of the con-
trol cells may have retained CMP-Neu5Ac bound to it
during the enzyme assay, whereas the mutant epimerase
did not; this would account for increased epimerase ac-
tivity in the sialuria extract. In the first case, the CMP-
Neu5Ac would bind and stabilize the epimerase but
would not inhibit its activity. In the second case, CMP-
Neu5Ac would not bind to the allosteric site of the mu-
tant epimerase. We consider this the simplest explana-
tion, but we cannot rule out the possibility that the pri-
mary mutations also allow for increased in vivo stability
of the epimerase, perhaps mediated by CMP-Neu5Ac
binding.
In the rat, the bifunctional epimerase gene was re-
ported to be expressed only in liver (Stasche et al. 1997),
whereas we found expression in a variety of tissues (fig.
3). It is likely that any tissue that synthesizes glycocon-
jugates would require the sialic acid syntheticmachinery.
Cloning, mutation analysis, and functional expression
studies have revealed the molecular mechanisms of sialic
acid accumulation in sialuria and have explained the
disorder’s inheritance pattern. Additional sialuria pa-
tients are required, to initiate genotype-phenotype cor-
relations. However, identification of the allosteric site of
UDP-GlcNAc 2-epimerase allows for immediate inves-
tigation into the interaction of CMP-Neu5Ac with the
enzyme. In particular, the issue of whether CMP-
Neu5Ac binds to the mutant epimerase can be addressed.
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